Parasagittal dural space hypertrophy and amyloid-β deposition in Alzheimer's disease

被引:5
作者
Song, Alexander K. [1 ,2 ]
Hett, Kilian [1 ]
Eisma, Jarrod J. [1 ]
McKnight, Colin D. [3 ]
Elenberger, Jason [1 ]
Stark, Adam J. [1 ]
Kang, Hakmook [4 ,5 ]
Yan, Yan [4 ]
Considine, Ciaran M. [1 ]
Donahue, Manus J. [1 ,2 ]
Claassen, Daniel O. [1 ,6 ]
机构
[1] Vanderbilt Univ, Dept Neurol, Med Ctr, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Vanderbilt Brain Inst, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Dept Radiol & Radiol Sci, Med Ctr, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Dept Biostat, Med Ctr, Nashville, TN 32732 USA
[5] Vanderbilt Univ, Ctr Quantitat Sci, Med Ctr, Nashville, TN 37232 USA
[6] Vanderbilt Univ, Dept Neurol, Cognit & Movement Lab, Med Ctr, 1500 21st Ave S 6, Nashville, TN 37212 USA
关键词
choroid plexus; parasagittal dural space; amyloid-beta; cerebrospinal fluid; glymphatics; NEUROPSYCHOLOGICAL STATUS RBANS; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; REPEATABLE BATTERY; BRAIN; CLEARANCE; SYSTEM; RECOMMENDATIONS;
D O I
10.1093/braincomms/fcad128
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
One of the pathological hallmarks of Alzheimer's and related diseases is the increased accumulation of protein amyloid-beta in the brain parenchyma. As such, recent studies have focused on characterizing protein and related clearance pathways involving perivascular flow of neurofluids, but human studies of these pathways are limited owing to limited methods for evaluating neurofluid circulation non-invasively in vivo. Here, we utilize non-invasive MRI methods to explore surrogate measures of CSF production, bulk flow and egress in the context of independent PET measures of amyloid-beta accumulation in older adults. Participants (N = 23) were scanned at 3.0 T with 3D T-2-weighted turbo spin echo, 2D perfusion-weighted pseudo-continuous arterial spin labelling and phase-contrast angiography to quantify parasagittal dural space volume, choroid plexus perfusion and net CSF flow through the aqueduct of Sylvius, respectively. All participants also underwent dynamic PET imaging with amyloid-beta tracer C-11-Pittsburgh Compound B to quantify global cerebral amyloid-beta accumulation. Spearman's correlation analyses revealed a significant relationship between global amyloid-beta accumulation and parasagittal dural space volume (rho = 0.529, P = 0.010), specifically in the frontal (rho = 0.527, P = 0.010) and parietal (rho = 0.616, P = 0.002) subsegments. No relationships were observed between amyloid-beta and choroid plexus perfusion nor net CSF flow. Findings suggest that parasagittal dural space hypertrophy, and its possible role in CSF-mediated clearance, may be closely related to global amyloid-beta accumulation. These findings are discussed in the context of our growing understanding of the physiological mechanisms of amyloid-beta aggregation and clearance via neurofluids.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Amyloid-β Immunotherapy for Alzheimer's Disease
    Fu, H. J.
    Liu, B.
    Frost, J. L.
    Lemere, C. A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (02) : 197 - 206
  • [32] Amyloid β deposition and glucose metabolism on the long-term progression of preclinical Alzheimer's disease
    Hatashita, Shizuo
    Wakebe, Daichi
    FUTURE SCIENCE OA, 2019, 5 (03):
  • [33] Biomarkers of inflammation and amyloid-β phagocytosis in patients at risk of Alzheimer disease
    Fiala, Milan
    Veerhuis, Robert
    EXPERIMENTAL GERONTOLOGY, 2010, 45 (01) : 57 - 63
  • [34] Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease
    Koertvelyessy, Peter
    Gukasjan, Angela
    Sweeney-Reed, Catherine M.
    Heinze, Hans-Jochen
    Thurner, Lorenz
    Bittner, Daniel M.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 46 (02) : 375 - 380
  • [35] Metals and amyloid-β in Alzheimer's disease
    Maynard, CJ
    Bush, AI
    Masters, CL
    Cappai, R
    Li, QX
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2005, 86 (03) : 147 - 159
  • [36] Alzheimer's Disease and the Amyloid-β Peptide
    Murphy, M. Paul
    LeVine, Harry, III
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 19 (01) : 311 - 323
  • [37] Monocytes in the Peripheral Clearance of Amyloid-β and Alzheimer's Disease
    Guo, Huifang
    Zhao, Zhaohua
    Zhang, Ruisan
    Chen, Peng
    Zhang, Xiaohua
    Cheng, Fan
    Gou, Xingchun
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 68 (04) : 1391 - 1400
  • [38] Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer's Disease
    Blennow, Kaj
    Hampel, Harald
    Zetterberg, Henrik
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 (01) : 189 - 201
  • [39] Alzheimer's disease amyloid-β pathology in the lens of the eye
    Moncaster, Juliet A.
    Moir, Robert D.
    Burton, Mark A.
    Chadwick, Oliver
    Minaeva, Olga
    Alvarez, Victor E.
    Ericsson, Maria
    Clark, John I.
    McKee, Ann C.
    Tanzi, Rudolph E.
    Goldstein, Lee E.
    EXPERIMENTAL EYE RESEARCH, 2022, 221
  • [40] Targeted proteomics in Alzheimer's disease:: focus on amyloid-β
    Portelius, Erik
    Zetterberg, Henrik
    Gobom, Johan
    Andreasson, Ulf
    Blennow, Kaj
    EXPERT REVIEW OF PROTEOMICS, 2008, 5 (02) : 225 - 237